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Diastolic heart failure (DHF) remains unexplained in some patients with recurrent admissions after full investigation. A study was
directed for screening SLE and systemic autoimmune connective tissue disorders in recurrent unexplained DHF patients admitted
at a short-stay and intermediate care unit. It was found that systemic autoimmune conditions explained 11% from all of cases.
Therapy also prevented new readmissions. Autoimmunity should be investigated in DHF.
1.Introduction
Diastolic heart failure (DHF) is a clinical syndrome in which
patients have symptoms and signs of heart failure (HF), nor-
mal left ventricular ejection fraction (LVEF), and evidence
of diastolic dysfunction. Recurrent DHF episodes are rare
when recognized triggers are corrected and therapy is appro-
priate. However, it remains unexplained in some patients
with recurrent admissions after full investigation. There
are no systematic data available upon recurrent DFH, and
few reports provide an underlying diagnosis. Interestingly,
Schwagten described DFH as a ﬁrst presentation of mixed
connective tissue disease [1].
Inﬂammation and autoimmunity are currently receiving
attention as mechanisms for DHF [2–6]. Impaired myocar-
dial dysfunction [7–11] has been conﬁrmed in Systemic
Lupus Erythematosus (SLE). Nevertheless, autoimmunity is
not routinely tested in DHF patients. There are not previous
reports in the literature which investigate autoimmunity as
the underlying cause of DHF.
2.Objectives
The main purpose of the study attempts to identify SLE
or systemic connective tissue disorders (SCTD) in recurrent
unexplained DHF patients. The secondary point was length
of readmission-free time under appropriate therapy.
3. Patients andMethods
3.1. Deﬁnition of Case and Study Population. Case was
deﬁned as unexplained recurrent DHF whom fulﬁlled SLE
or STCD classiﬁcation criteria.
3.2. Deﬁnition of Unexplained Recurrent DHF. DHF was
deﬁned as (1) symptoms and signs of heart failure described
in the guidelines published by the American Heart Associa-
tion [12] and European Society of Cardiology [13]; (2) LVEF
over55%andaltereddiastolicﬁllingpattern;and(3)absence
of hypokinesis or ventricle dilation, on echocardiogram.2 Clinical and Developmental Immunology
Recurrentwasconsideredtwoormoreadmissionswithin
last year under appropriate treatment and absence of precip-
itant factors. Patients had received diuretics and angiotensin
converter enzyme inhibitors. Hydric balance, salt intake,
blood pressure, atrial ﬁbrillation, or valve involvement were
not triggers and must be stable at admission.
Unexplained implied unidentiﬁable cause after investi-
gation, including routine blood count, complete serum and
urine biochemistry, troponin and thyroid hormones, chest
X-rays, continuous electrocardiography monitorization and
new echocardiography. Infection, coronary ischemia, ane-
mia, hypothyroid or hyperthyroid state were ruled out. Pul-
monary embolism was investigated, even in anticoagulated
patients, by angioCT scan when D-dimmer was positive or
there was suggestive echocardiography.
3.3. Diagnosis of Autoimmune Condition. Common SLE/
SCTD symptoms and signs were evaluated. STCD comprised
APS, Sj¨ ogren Syndrome (SS), Mixed Connective Tissue
Disease (MCTD), and Undiﬀerentiated Connective Tissue
Disease (UCTD). Physicians were guided by a nonvalidated
internal consensus questionnaire, which contained 17 items
(see the appendix). Clinical pattern was accepted as probable
SLE/SCTD when fulﬁlled 3 or more items.
Immunological tests were only requested when this clin-
ical pattern was presented and accepted after two repeated
positive determinations. Immunology tests included anti-
nuclearantibodies(ANAs),anticardiolipinantibodies(aCL),
anti-β2-glycoprotein I antibodies (anti-β(2) GPI), anti-DNA
antibodies, thyroglobulin autoantibodies (anti-TGB) and
thyroid peroxidase autoantibodies (anti-TPO). Anti-TGB
and anti-TPO were decided due to given association between
rheumatic heart disease and autoimmune thyroid disease
[14].
Recurrent unexplained DFH patients whom fulﬁlled
probable SLE/SCTD with positive immunology were revalu-
atedbyatrainedphysicianonsystemicautoimmuneconnec-
tive tissue disorders. Moreover, this physician only selected
those cases whom fulﬁlled correct diagnosis and evident
SLE/APS/SCTD classiﬁcation criteria [15, 16]. Alarcon-
Segovia [17] and European Consensus Group [18] classi-
ﬁcation criteria were used for MCTD and SS, respectively.
UCTD was restrictively considered, for research purposes,
when clinical and immunological features did not fulﬁlled
classiﬁcation criteria for those conditions but usual clinical
practiceactuallysuggesteddiseaseandrecommendedfurther
followup expecting new criteria in the outcome or investiga-
tions. Patients with similar proﬁle but insuﬃcient data were
not included, although they will be brieﬂy commented.
3.4. Study, Protocol, and Phases. A prospective observational
study was performed between July 2007 and November 2009
at a short-stay and intermediate care unit (UARH) of the
University Hospital Santander, Spain. The study was divided
in Phase I, Phase II, and Phase III (Figure 1), using an iden-
tical evaluation protocol.
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Figure 1: Protocol and phases. HF: Heart failure, DHF: Diastolic
heart failure.
Phase I was conducted between July 2007 and September
2008, for main objective. Cases were recruited from consecu-
tive admitted heart failure patients. Systolic dysfunction and
absence of recent echocardiography were exclusion criteria.
History, clinical ﬁndings, laboratory results, and imaging
were integrated by the clinicians in charge, which ﬁnally
made the diagnosis of unexplained recurrent DHF. Second
screening was subsequently directed for SLE/SCTD in those
DHF patients, who underwent questionnaire and regular
followup with immunology tests. Those who fulﬁll probable
SLE/SCTD criteria were revaluated by an expert physician,
who ﬁnally considered cases when patients with correct
diagnosis met classiﬁcation criteria for SLE/APS/SCTD.
Phase II was conducted until October 2008, for sec-
ondary objectives. Cases were treated and outcome was
observed. Detailed regimens will be discussed in results.
Free-admission time, readmission rate, and therapeutic
changes by other specialists were registered.
Phase III was conducted between October 2008 and
November 2009. Cases were referred to respective competent
departments (Cardiology, Hematology, Rheumatology, and
Internal Medicine) for specialized long-term followup. WeClinical and Developmental Immunology 3
Table 1: Cases characteristics (n = 5).
Age 74 years (65y–80y)
Gender 100% female (5)
Ethnicity White South
European
Allergies or urticaria 80% (4)
Polyarticular rheumatism 100% (5)
Thyroid problems 60% (3)
Miscarriages and obstetric morbidity 20% (1)
Raynaud 40% (2)
Livedo reticularis 60% (3)
Leucopenia 40% (2)
Previous positive autoantibody tests 80% (4)
Antithyroid autoantibodies positive 40% (2)
Autoimmune condition previously
diagnosed 0% (0)
Secondary Hypertension 80% (4)
Rheumatic mitral lesion 40% (2)
Atrial ﬁbrillation 100% (5)
Pulmonary thromboembolism 20% (1)
Autoantibodies positive 100% (5)
ANAs positive >1/340 80% (4)
aCL positive 40% (2)
SLE 40% (2)
APS 20% (1)
UCTD 60% (3)
observed outcome and registered therapy and diagnosis
changes. Free-readmission and readmission rate time were
also listed again.
4. Results
4.1. Phase I. 629 heart failure patients were admitted in
Phase I. Only 187 patients had prior echocardiogram and
showed nonsystolic heart failure (30%); 442 patients were
excluded. From them, 44 patients were classiﬁed as recurrent
and unexplained DHF (Figure 1).
Finally, 5 patients (11%) fulﬁlled the deﬁnition of case
(Table 1).
4.2. Cases Description
4.2.1. Case 1. Case 1 was an 80-year-old woman with
past history of penicillin allergy, secondary hypertension,
polyarticular rheumatism in adolescence, thyroid surgery
in adulthood, and current mild renal failure, with nonin-
vestigated hematuria. She had been diagnosed osteoarthri-
tis because of joint pains, joint eﬀusion on knees, and
ANA 1/160, by rheumatology department ten years ago.
She had been followed due to rheumatic double mitral
lesion by cardiology department for 13 years, but she had
not needed interventions and recent LVEF was normal.
She referred Raynaud phenomena, chronic asthenia, malar
rash and photosensitivity, which have been improved with
age; she had livedo reticularis, joints eﬀusions on wrist,
knees and ankles. She had shown chronic leucopenia
(<4000/mL) on past blood counts. Immunology tests dem-
onstrated myeloperoxidase-anti-neutrophil-cytoplasmic an-
tibodies (MPO-ANCA) > 100, and anti-β(2)GPI 24. She
fulﬁlled diagnosis criteria and 5 classiﬁcation criteria for
SLE, with antiphospholipid antibodies. MPO-ANCA may be
observed until 25% of SLE patients, with activity correlation.
Renal, heart, and thyroid disease were not invasively assessed
searching more criteria.
4.2.2. Case 2. Case 2 was a 67-year-old woman, with past
history of metamizol allergy, late onset hypertension, and
asthma. She had been diagnosed with amiodarone-induced
hyperthyroidism, although she had showed repeated high
titers of anti-TPO. Amiodarone was only given for some
months and deﬁnitively discontinued. She had started being
followedduetorheumaticdoublemitrallesionbycardiology
department last year after one episode of heart failure admis-
sion. She had undergone anticoagulant therapy. She had
rashes, photosensitivity, chronic symmetric distal polyartic-
ular joint pain and swelling, Raynaud phenomena, asthenia,
and cognitive impairment. She presented livedo reticularis
and joint eﬀusions on physical examination, and erythema
was conﬁrmed in followup. Brain CT scan demonstrated
multiple lacunar infarcts, although acenocoumarol levels
were adequate. Immunology tests showed ANA > 1/1280 but
aCL and repeated anti-TPO were negative. Libmann-Sacks
endocarditis was not found on repeated echocardiography.
She fulﬁlled diagnosis criteria and 4 classiﬁcation criteria for
SLE.
4.2.3. Case 3. Case 3 was an 80-year-old woman, with past
history of metamizol allergy, constrictive pericarditis, and
heart failure. She referred facial rashes, signiﬁcant photo-
sensitivity, Raynaud phenomena, sicca syndrome, relapsing
asthenia periods, and swelling and joint pains on wrists,
knees, and ankles. Dermatological and joint signs were
conﬁrmed on examination. Blood account showed leucope-
nia. Initial immunology tests demonstrated ANA 1/320
and anti-β(2)GPI 33, which remained repeatedly positive.
Echocardiogram showed a 70mm left auricle and diastolic
dysfunction.Case-resembledSLEorSS,butshewasclassiﬁed
as UCTD with antiphospholipid autoantibodies, due to
absence of suﬃcient criteria.
4.2.4. Case 4. Case 4 was a 67-year-old woman, with
intricate past history. She suﬀe r e do n em i s c a r r i a g ea ts e c o n d
pregnancy trimester and an antenatal death due to preterm
fetus. Then, she developed an episode of 9-month-length
unexplained fever and joints pain when she was 42 years old.
She had suﬀered two episodes of labeled transient ischemic
attack, when she was 51 and 54 years old. However, the sec-
ond one consisted of new onset headache and sensitivity loss
during 3 months. Finally, she was diagnosed with recurrent
periorbital rash and hypothyroidism by Allergy Department
inlastyear.Shereferredrecurrentrashﬂairs,eyedryness,and4 Clinical and Developmental Immunology
Raynaudphenomena. She hadresidual periorbital erythema,
a round bright hyperkeratosic pink plaque on ankle, and
livedo reticularis. Immunology tests showed ANA 1/1280
andanti-TPO507.Theonlyechocardiographichallmarkwas
a 48mm left auricle and diastolic dysfunction. Case resem-
bled SLE/ APS/SS, but she was classiﬁed as UCTD, in the
absence of suﬃcient criteria.
4.2.5. Case 5. Case 5 was an 80-year-old woman with
rheumatic double mitral lesion which required prosthetic
replacement when she was 68 years old. However, she
underwent new replacement due to unexplained early valve
dysfunction two years later. She had been admitted after
secondsurgeryinmultipleoccasionsbecauseofheartfailure,
although repeated echocardiography showed both normal
valve and LVEF. She had been also evaluated due to pol-
yarthritis, uveitis, anemia, and ANA 1/320 ﬁve years ago, but
without deﬁnitive conclusions. ANA was repeated and re-
mained positive (1/320). She was classiﬁed as UCTD.
4.3. Phase II. All of cases have been treated on angiotensin
enzyme converter inhibitors, acenocoumarol, and diuretics,
which were continued.
Azathioprine 50mg pd. was given to Case 1. Initial
methylprednisolone bolus (1.5g), azathioprine 50mg pd.,
and hydroxychloroquine 200mg pd. were given to Case 2.
Hydroxychloroquine 200mg pd. was selected for the other
three cases. Diuretics were reduced in all of cases. Case 2
required increasing diuretics after complete discontinuation
of treatment by Surgery Department, 6 months later. More-
over, methimazole was discontinued in Case 2 but thyroid
hormones continued normally during Phase II. Echocardio-
grams were not repeated again at Phase II.
There were not new admissions due to DHF within
Phases I and II. The admission-free time was, respectively,
11, 26, 11, 5, and 5 months. Case 1 was readmitted because
of pulmonary embolism two months after diagnosis, and she
was reclassiﬁed as SLE and secondary APS.
4.4. Phase III. We refer all of cases to Cardiology, Rheuma-
tology, and Internal Medicine Departments. SLE and UCTD
diagnosis were criticized but APS were accepted. Patients
did not received an alternative diagnosis, and we understand
that they were considered false-positive autoantibody cases.
Immunosuppressive agents were discontinued. Cases 1, 2,
and 3 readmitted. The admission-free mean time was two
monthsaftertherapychanges.Cases1and2neededIntensive
Care Unit in the ﬁrst readmission. Case 1 died due to heart
failure and retroperitoneal hemorrhage after a long three-
month admission. Case 2 was readmitted again 7 months
later.
5. Discussion
Systemic autoimmune connective tissue disorders explained
11% from recurrent unexplained DFH admissions in this
study.
DHF is determined by abnormal diastolic ﬁlling of left
ventricle.Itmaybeprecipitatedbyhemodynamicstressfrom
cardiovascular (e.g., tachycardia, hypertension) or other ori-
gin (e.g., infection, anemia). DHF usually is easily managed
when triggers are corrected; therefore, recurrences are not
expected. Nevertheless, absence of evident cause may be
followed by new episodes. We usually observe unexplained
recurrent DHF episodes in patients whom accumulate
suggestive data of autoimmune background. We believe that
chronic uncontrolled systemic inﬂammation hinders ade-
quate diastolic ﬁlling as other studies reported [10, 19].
However, few studies attempt to investigate underlying auto-
immunity in heart failure patients.
The case proﬁle was an elderly woman with past
history of allergies, rashes, chronic polyarticular involve-
ment, thyroid disease, secondary hypertension, rheumatic
mitral lesion, and ANA positive. Surprisingly, no case had
presented rheumatic fever features in childhood. SLE and
APScausesimilarvalveinvolvement[20].Ontheotherhand,
Hashimoto’s thyroiditis has been already linked to rheumatic
heart disease [14], so we could speculate about possible
unrecognized systemic autoimmune diseases. Thus, we be-
lieve rheumatic description on echocardiography should be
taken cautiously and should be further investigated.
In the same way, we think that elderly age of cases
demonstrated delayed diagnosis and evolution of uncon-
trolled inﬂammation. Although young patients may display
more autoimmune activity and diastolic dysfunction, overt
heart failure is unlikely to expect, as in nonautoimmune
patients. We did not found DHF patients under 50 years old.
Therefore, elder patients should not be excluded without an
appropriate history. With respect of this, osteoarthritis or
hypertension must be dated in order to decide whether they
are primary or consequence of previous inﬂammation.
Moreover, speciﬁc therapy seemed to prevent readmis-
sion and discontinuation of medications. Inversely, with-
drawalwasdramaticallyassociatedtoreadmissionsafterlong
symptom- free periods.
Therefore, we could state that autoimmunity, particu-
larly SLE/SCTD, should be always considered within DHF
patients.
Study was designed to answer whether autoimmune
connective tissue disorders explained recurrent episodes, but
notforeveryepisodeorotherautoimmunediseases.Perhaps,
aﬀected males or vasculitis should be investigated following
diﬀerent protocols. We cannot conclude that autoimmune
DFH patients fulﬁll the proposed proﬁle. In fact, we found
one patient with bronchiolitis and vasculitis, who did not
satisfy our criteria. We did not know if DHF or even any type
of heart failure should be always investigated. We noticed a
posteriori that study excluded 6 similar patients. As well as, 8
excluded patients showed rheumatic heart disease.
Likewise,itdoesnotanswerifimmunologytestsarevalid
or/and cost-eﬃcient although clinical pattern was absent.
Prevalence studies for underlying autoimmune diseases are
needed. On other hand, other DHF causes should be
investigated.Clinical and Developmental Immunology 5
Finally, the study design did not include controls to com-
pare admission-free mean times. Conclusions on therapy
remain intuitive.
We tried to explain the events on Phase III. Phase III
intended congruency among physicians and second opinion
for patients. Unfortunately, we did not expect the dramatic
outcome of Cases 1 and 2. We searched reasons on the clas-
siﬁcation criteria misuse by inexpert and strict physicians.
Patientswereinformedaboutpossiblechangesbuttheycom-
plained after discontinuation of a regimen felt as beneﬁcial.
Ethical issues and consensus should be improved on new
experimental clinical research about autoimmunity.
6. Conclusions
Autoimmunity is an important mechanism of diastolic dys-
function.Autoimmuneconnectivetissuedisordersshouldbe
considered in patients with recurrent DHF. Speciﬁc therapy
may improve patients and prevent readmissions. Elderly
patients should not be excluded from investigations. Rheu-
matic heart disease should be reconsidered in suspicion of
systemic disease. More studies are warranted for clarifying
prevalenceofunderlyingautoimmunity,forsystematicexpo-
sition of other DHF causes, and for cost-eﬀectiveness of
immunological tests.
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Appendix
Questionnaire
SYMPTOMS
 CLINIC DATA
1 AGE
Age 15–45 years-old
Age >45–55 years-old
2 VASCULARRISKFACTORS
Not
Yes
3 Pilladverse efects
Yes
Not
4 DVT/PE
Yes
Not
5 Migrain
Yes
Not
6 Cognitive impairment
Yes
Not
7( n o . ) Miscarriages
Yes
Not
8 Obstetric complications
Yes
Not
9 Familiar background (SLE, etc.)
Yes
Not
10 Dermatology (erythema, photosensitivity,
aphtae, alopecia, Raynaud)
Yes
Not
11 Joint involvement
Yes
No
PHYSICAL EXAMINATION
 SIGNS
12 L´ IVEDORETICULARIS
Yes
Not
13 FACIALERYTHEMA
Yes
Not
14 MOUTH ULCERS
Yes
Not
15 ALOPECIA
Yes
Not
16 PERIUNGEALLESIONS
Yes
Not
17 ARTHRITIS HANDS/FEET
Yes
Not
REQUEST AUTOANTIBODIES
APS(∗)A P A , A N A
SLE ANA, C3,C4,Ch50
Vasculitis ANA, ANCA p y c
ANA + anti-DNA, Anti Ro, anti
La
APA+ Repeat 6 weeks
(∗) APS: when at least 2 items (no. 1–9, 12)6 Clinical and Developmental Immunology
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